# Source note: Patrick Soon-Shiong / Anktiva / immune-system cancer claim

Date: 2026-06-18
Section: Health / cancer immunotherapy / source-card review
Public article: https://managingexpectations.net/blog/articles/patrick-soon-shiong-anktiva-immunotherapy-source-card.html
Original source lead: Facebook screenshots supplied by Chris from page `Engineering & Science`, public post marker visible, timestamp visible as `2d`.
Local/public image assets saved:
- `assets/images/health/patrick-soon-shiong-anktiva-immunotherapy-source-card.jpg`
- `assets/images/health/patrick-soon-shiong-anktiva-immunotherapy-source-card-part-2.jpg`
- `assets/images/health/patrick-soon-shiong-anktiva-immunotherapy-source-card-part-3.jpg`
- `assets/images/health/patrick-soon-shiong-anktiva-immunotherapy-source-card-meme.jpg`

## Visible Facebook claim

The visible text across the screenshots says Dr. Patrick Soon-Shiong is a billionaire physician-scientist, entrepreneur and founder of ImmunityBio, and describes Anktiva / N-803 as an immunotherapy designed to support the body's natural defenses against `c@ncer`. It says Anktiva stimulates key parts of the immune system, including natural killer cells and cytotoxic T-cells. Later screenshots say his work has attracted worldwide attention because it focuses on harnessing the immune system's natural capabilities and that Anktiva is a notable immunotherapy development.

The attached meme/image text says: `This billionaire physician-scientist developed a cancer treatment designed to boost the body's natural killer cells without using chemotherapy. Sadly, not many people know his name.` The screenshot shows visible engagement of approximately `29.9K` reactions and `4.8K shares`.

## Sources checked

- FDA approval notice, April 22, 2024: `FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer`.
  - URL: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer
  - Key facts: FDA approved Anktiva with BCG for adult patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors; QUILT-3.032; CR 62%; DOR >=12 months in 58% of responders and >=24 months in 40%.
- FDA prescribing information / label PDF.
  - URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761336s000lbl.pdf
  - Key facts: Anktiva is an IL-15 receptor agonist; for intravesical use only; warning that delaying cystectomy can lead to metastatic bladder cancer; mechanism includes NK, CD8+ and memory T-cell activation.
- PubMed PMID 38953850.
  - `N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review.`
  - Supports overview of N-803/Anktiva with BCG trial context and reported response figures.
- PubMed PMID 38226931.
  - `Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin...`
  - Supports QUILT-3.032 patient-reported outcomes / quality-of-life context.
- ImmunityBio SEC Form 10-K filed 2026-02-23.
  - URL: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231.htm
  - Key facts: identifies Dr. Patrick Soon-Shiong as Executive Chairman and Global Chief Scientific and Medical Officer; describes him as physician-scientist/inventor and credits him with Abraxane.

## Evidence labels

- Confirmed: Anktiva/N-803 is FDA-approved in combination with BCG for a defined BCG-unresponsive NMIBC with CIS indication.
- Confirmed: label mechanism involves IL-15 receptor agonism and activation/proliferation of NK, CD8+ and memory T cells.
- Supported but bounded: QUILT-3.032 response data in the defined bladder-cancer population.
- Not established: general cancer-cure claims, use for all cancers, or replacement of oncology-directed treatment.

## Editorial framing

Treat the Facebook post as a lead. Use careful language: `FDA approved for`, `label describes`, `trial reported`, `social post says`. Include medical caution and the delayed-cystectomy warning. Do not provide dosing instructions beyond high-level description of approved indication, and do not tell patients to seek or avoid the drug.